Haverford Trust CO Bristol Myers Squibb CO Transaction History

Haverford Trust CO

$9.48 Billion
Q2 2024

A detailed history of Haverford Trust CO transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Haverford Trust CO holds 66,847 shares of BMY stock, worth $3.46 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

66,847

Previous 71,716 6.79%

Holding current value

$3.46 Million

Previous $3.89 Million 28.62%

% of portfolio

0.03%

Previous 0.04%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$40.25 - $52.99 $195,977 - $258,008	-4,869 Reduced 6.79%	66,847 $2.78 Million
Q1 2024 May 02, 2024	SELL	$47.98 - $54.4 $313,069 - $354,960	-6,525 Reduced 8.34%	71,716 $3.89 Million
Q4 2023 Feb 08, 2024	BUY	$48.48 - $57.85 $73,592 - $87,816	1,518 Added 1.98%	78,241 $4.01 Million
Q3 2023 Nov 09, 2023	SELL	$57.89 - $64.73 $355,097 - $397,053	-6,134 Reduced 7.4%	76,723 $4.45 Million
Q2 2023 Aug 08, 2023	SELL	$63.71 - $70.74 $92,889 - $103,138	-1,458 Reduced 1.73%	82,857 $5.3 Million
Q1 2023 May 12, 2023	SELL	$65.71 - $74.53 $20,238 - $22,955	-308 Reduced 0.36%	84,315 $5.84 Million
Q4 2022 Feb 13, 2023	SELL	$68.48 - $81.09 $206,056 - $243,999	-3,009 Reduced 3.43%	84,623 $6.09 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $432 - $255,416	-3,324 Reduced 3.65%	87,632 $6.23 Million
Q2 2022 Aug 12, 2022	BUY	$72.62 - $79.98 $39,723 - $43,749	547 Added 0.61%	90,956 $7 Million
Q1 2022 May 05, 2022	BUY	$61.48 - $73.72 $444,561 - $533,069	7,231 Added 8.69%	90,409 $6.6 Million
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $122,919 - $143,295	-2,292 Reduced 2.68%	83,178 $5.19 Million
Q3 2021 Nov 12, 2021	SELL	$59.17 - $69.31 $58,696 - $68,755	-992 Reduced 1.15%	85,470 $5.06 Million
Q2 2021 Aug 16, 2021	BUY	$61.91 - $67.42 $5 Million - $5.44 Million	80,685 Added 1396.66%	86,462 $5.78 Million
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $4.77 Million - $5.19 Million	-77,008 Reduced 93.02%	5,777 $5.78 Million
Q1 2021 May 12, 2021	SELL	$59.34 - $66.74 $187,099 - $210,431	-3,153 Reduced 3.67%	82,785 $5.23 Million
Q4 2020 Feb 05, 2021	BUY	$57.74 - $65.43 $305,271 - $345,928	5,287 Added 6.56%	85,938 $5.33 Million
Q3 2020 Nov 10, 2020	BUY	$57.43 - $63.64 $50,997 - $56,512	888 Added 1.11%	80,651 $4.86 Million
Q2 2020 Aug 13, 2020	SELL	$54.82 - $64.09 $118,356 - $138,370	-2,159 Reduced 2.64%	79,763 $4.69 Million
Q1 2020 May 11, 2020	BUY	$46.4 - $67.43 $38,094 - $55,360	821 Added 1.01%	81,922 $4.57 Million
Q4 2019 Feb 10, 2020	BUY	$49.21 - $64.19 $279,414 - $364,470	5,678 Added 7.53%	81,101 $5.21 Million
Q3 2019 Nov 04, 2019	SELL	$42.77 - $50.71 $100,723 - $119,422	-2,355 Reduced 3.03%	75,423 $3.83 Million
Q2 2019 Aug 13, 2019	BUY	$44.62 - $49.34 $1,383 - $1,529	31 Added 0.04%	77,778 $3.53 Million
Q1 2019 May 09, 2019	BUY	$45.12 - $53.8 $71,018 - $84,681	1,574 Added 2.07%	77,747 $3.71 Million
Q4 2018 Feb 12, 2019	SELL	$48.76 - $63.23 $201,330 - $261,076	-4,129 Reduced 5.14%	76,173 $3.96 Million
Q3 2018 Nov 08, 2018	SELL	$55.19 - $62.25 $68,545 - $77,314	-1,242 Reduced 1.52%	80,302 $4.99 Million
Q2 2018 Aug 10, 2018	SELL	$50.53 - $62.98 $256,136 - $319,245	-5,069 Reduced 5.85%	81,544 $4.51 Million
Q1 2018 May 09, 2018	BUY	$59.92 - $68.98 $258,434 - $297,510	4,313 Added 5.24%	86,613 $5.48 Million
Q4 2017 Feb 13, 2018	BUY	$59.94 - $65.35 $243,835 - $265,843	4,068 Added 5.2%	82,300 $5.04 Million
Q3 2017 Nov 09, 2017	BUY	$55.23 - $63.74 $152,434 - $175,922	2,760 Added 3.66%	78,232 $4.99 Million
Q2 2017 Aug 14, 2017	BUY	N/A	75,472	75,472 $4.21 Million

Others Institutions Holding BMY

# of Institutions

2,402

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $110B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Haverford Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Haverford Trust CO with notifications on news.

Account

Haverford Trust CO Bristol Myers Squibb CO Transaction History